[177Lu]Lu-RTX-2358
Phase 1
[177Lu]Lu-RTX-2358 is one of 11 therapeutic programs targeting Metastatic Non Small Cell Lung Cancer. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
10 competitors in Metastatic Non Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
DATROWAY
Daiichi SankyoPhase 3
Paraplatin
AAvyxa
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Alimta
GGynecologic Oncology Group
Phase 3
Platinum Based Chemotherapy
RochePhase 3
LN-145
IIovance Biotherapeutics, Inc.
Phase 2
Taxol
TevaPreclinical
Abraxane
Bristol-Myers SquibbPreclinical
BMS-986504
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Non Small Cell Lung Cancer1 trial
A Single-Center, Prospective, Open-Label, Investigator-Initiated Study Evaluating the Safety, Biodistribution, Radiation Dosimetry, and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT07689643·36 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for [177Lu]Lu-RTX-2358. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]